John V Heymach, MD, PhD
Cascone T et al. NeoCOAST-2: A randomized, open-label, phase 2 study of neoadjuvant durvalumab plus novel immunotherapies and chemotherapy (CT) followed by adjuvant durvalumab plus novel agents, in patients with resectable non-small-cell lung cancer (NSCLC). AACR 2022;Abstract CT124.
Chen L et al. Metastasis is regulated via microRNA-2009/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Comm 2014;5:5241. Abstract
Forde PM et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med 2022;386(21):1973-85. Abstract
Heymach JV et al. AEGEAN: A phase 3 trial of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC. AACR 2023;Abstract CT005.
O’Brien M et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): An interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncology 2022;23(10):1274-86. Abstract
Paz-Ares L et al. Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study. Ann Oncol 2022;33(4):451. Abstract
Spigel DR et al. Five-year survival outcomes from the PACIFIC trial: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J Clin Oncol 2022;40(12):1301-11. Abstract
Helena Yu, MD
Ahn MJ et al. MET biomarker-based preliminary efficacy analysis in SAVANNAH: Savolitinib+osimertinib in EGFRm NSCLC post-osimertinib. IASLC 2022;Abstract EP08.02-140.
Jänne PA et al. Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer. Cancer Discov 2022;12(1):74-89. Abstract
Mazieres J et al. Tepotinib + osimertinib for EGFRm NSCLC with MET amplification (METamp) after progression on first-line (1L) osimertinib: Initial results from the INSIGHT 2 study. ESMO 2022;Abstract LBA52.
Tsuboi M et al. Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA. ESMO 2022;Abstract LBA47.
Corey J Langer, MD
Drilon A et al. Long-term efficacy and safety of entrectinib in ROS1 fusion-positive NSCLC. JTO Clin Res Rep 2022;3(6):100332. Abstract
Griesinger F et al. Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: Update from the ARROW trial. Ann Oncol 2022;33(11):1168-78. Abstract
Li W et al. The efficacy and safety of taletrectinib in patients with TKI-naïve or crizotinib-pretreated ROS1-positive non–small cell lung cancer (NSCLC). J Clin Oncol 2022;40(16_suppl):8572. Abstract
Shiba-Ishii A et al. Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer. Nat Cancer 2022;3(6):710-22. Abstract
Soda M et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448(7153):561-6. Abstract
Solomon B et al. Updated efficacy and safety from the phase 3 CROWN study of first-line lorlatinib vs crizotinib in advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). AACR 2022;Abstract CT223.
Tiseo M et al. Brigatinib (BRG) vs crizotinib (CRZ) in anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor-naive ALK+ non-small cell lung cancer (NSCLC): ALTA-1L final results. ELCC 2022;Abstract 29P.
David R Spigel, MD
Camidge DR et al. Telisotuzumab vedotin (Teliso-V) monotherapy in patients (pts) with previously treated c-Met–overexpressing (OE) advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2022;40(16_supp):9016. Abstract
de Langen AJ et al. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: A randomised, open-label, phase 3 trial. Lancet 2023;401(10378):733-46. Abstract
Goto K et al. Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-mutant metastatic non-small cell lung cancer (NSCLC): Interim results from the phase 2 DESTINY-Lung02 trial. ESMO 2022;Abstract LBA55.
Harada G et al. Rare molecular subtypes of lung cancer. Nat Rev Clin Onc 2023;20:229-49. Abstract
Li BT et al. Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. N Engl J Med 2022;386(3):241-51. Abstract
Nakagawa K et al. Trastuzumab deruxtecan in HER2-overexpressing metastatic non-small cell lung cancer: interim results of DESTINY-Lung01. IASLC/WCLC 2020;Abstract OA04.05.
Veillon R et al. Safety of tepotinib in patients with MET exon 14 skipping NSCLC and recommendations for management. Clin Lung Cancer 2022;23(4):320-32. Abstract
Edward B Garon, MD, MS
Brahmer JR et al. Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer in CheckMate 227. J Clin Oncol 2023;41(6):1200-12. Abstract
Gogishvili M et al. Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: A randomized, controlled, double-blind phase 3 trial. Nat Med 2022;28(11):2374-80. Abstract
Johnson ML et al. Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: The phase III POSEIDON study. J Clin Oncol 2023;41(6):1213-27. Abstract
Ozguroglu M et al. Three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non-small cell lung cancer (NSCLC): The EMPOWER-Lung 1 trial. ESMO 2022;Abstract LBA54.
Paz-Ares LG et al. First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients (pts) with metastatic non–small cell lung cancer (NSCLC): 3-year update from CheckMate 9LA. ASCO 2022;Abstract LBA9026.
Ticiana Leal, MD
Leal TA et al. Lung-MAP: A collaborative roadmap to improve cancer outcomes. J Clin Oncol 2022;40(21):2285-87. Abstract
Levy B et al. Peer pressure: How well do you know your ADCs? Answers to key questions about antibody–drug conjugates in NSCLC. TTLC 2023;Discussant.
Levy B et al. TROPION-Lung02: Initial results for datopotamab deruxtecan plus pembrolizumab and platinum chemotherapy in advanced NSCLC. WCLC 2022;Abstract MA13.07.
Reckamp KL et al. Phase II randomized study of ramucirumab and pembrolizumab versus standard of care in advanced non-small-cell lung cancer previously treated with Immunotherapy-Lung-MAP S1800A. J Clin Oncol 2022;40(21):2295-306. Abstract
Rosner S et al. Antibody-drug conjugates for lung cancer: Payloads and progress. ASCO Educational Book 2023;Abstract e389968.
Villaruz LC et al. Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death-ligand 1 inhibitors in non-small cell lung cancer. Cancer 2023;129(9):1319-50. Abstract